Long-Term PF-06651600 for the Treatment of Alopecia Areata
Status:
Recruiting
Trial end date:
2024-07-06
Target enrollment:
Participant gender:
Summary
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational
study drug (called PF-06651600) in adults and adolescents (12 years and older) who have
alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015
(NCT03732807) will have an opportunity to enroll as well as patients who have not previously
participated in either of these studies. The study is open-label and all patients entering
the study will receive active study drug.
A sub-study of approximately 60 adult patients who are participating in the B7981032 study
will be conducted at select sites in the US and Canada. The sub-study will evaluate the
immune response to tetanus and meningococcal vaccines in patients who have received a minimum
of 6 months of 50 mg PF-06651600.